Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
March 05, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces $87.4 Million Private Placement
March 04, 2024 09:45 ET
|
Perspective Therapeutics, Inc.
SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Participate at Upcoming Investor Conferences
February 26, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
February 01, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based...
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
January 22, 2024 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
January 18, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces Proposed Public Offering
January 17, 2024 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
January 17, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in...
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
January 09, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NETLantheus will have the option to co-fund and negotiate an exclusive license for certain...